Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2023	Mar. 31, 2022
Consolidated Statements of Operations [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	46,371	30,794
General and administrative	15,823	11,770
Total operating expenses	62,194	42,564
Loss from operations	(62,194)	(42,564)
Interest expense	(468)	(464)
Interest and other income, net	1,908	623
Accretion of discount and amortization of premium on investments, net	2,419	(577)
Net loss	$ (58,335)	$ (42,982)
Net loss per share - basic (in dollars per share)	$ (0.73)	$ (0.67)
Net loss per share - diluted (in dollars per share)	$ (0.73)	$ (0.67)
Weighted-average common shares outstanding - basic (in shares)	79,453,519	64,509,721
Weighted-average common shares outstanding - diluted (in shares)	79,453,519	64,509,721

The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585